This is exemplified by the identification of chromatin interactions between MS associations and the IL20RA and IL22RA2 genes, showing a potential use of anti-IL20 therapy in MS, and highlights the potential of Capture Hi-C to provide novel therapeutic targets or drug repositioning to improve patient outcome. This evidence concerns the gene IL20 and myeloid sarcoma.